Why Is ASCENDIS PHARMA A/S (ASND) Stock Up Today?

Why ASND stock is up today

Ascendis Pharma A/S stock rose 5.95% to $262.67 in morning trading, driven by the company's announcement of a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical. The resolution of ongoing patent disputes and the terms of the agreement, including royalty payments, have drawn investor attention and sparked a positive intraday move.

What Happened

Ascendis Pharma and BioMarin announced a binding term sheet for a global settlement and license agreement related to YUVIWEL (navepegritide). Under the agreement, BioMarin will receive a 20% royalty on net sales of Yuviwel in the U.S., EU, Brazil, and South Korea. The agreement resolves all pending patent-related proceedings between the two companies. The announcement was made by both companies, with Ascendis disclosing the move from Copenhagen and BioMarin from San Rafael, California.

Retail traders on r/wallstreetbets are calling the stock oversold, and the stock has printed five fresh 52-week highs on August 31. Additionally, Jean Jacques Bienaime, a director of Ascendis, and Scott Thomas Smith, the company's CFO, have both made recent purchases, signaling confidence among insiders.

What The Data Shows

The stock opened at $247.25 and reached a session high of $264.87 at 9:40 AM ET. The current price of $262.67 represents a significant intraday gain. The volume so far is 0.1 million shares, which is 0.1 times the 3-month daily average. Over the last eight sessions, the stock had declined 4.5% from $259.62 to $247.91 before today's rally. The stock is trading within its 52-week range of $186.05 to $282.15.

What To Watch

Ascendis Pharma does not have an upcoming earnings date listed. Investors should monitor the breadth of coverage and analyst ratings as the stock continues to trade near its 52-week high.